Τίτλος:
A phase II study of the docetaxel-carboplatin chemotherapy regimen in
advanced non-small-cell lung cancer
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
The efficacy of the docetaxel-carboplatin combination chemotherapy was
studied in various phase II studies. Based on these data we aimed to
test the regimen in previously untreated patients with advanced advanced
non-stroking lung cancer (NSCLC) with docetaxel 80 mg/m(2) a standard
dose of carboplatin at AUC = 5, in an attempt to define the efficacy and
tolerability of the combination in an open-label phase II study.
Patients with histologically confirmed advanced NSCLC stage IIIB and IV
were candidates for the present study. Docetaxel was administered at 80
mg/m(2) over 1 h by intravenous (IV) infusion followed by carboplatin
AUC = 5 in 30 min IV infusion, both on day 1, and recycled every 21
days. Sixty patients received 263 courses of therapy in total; 231/263
(88%) were administered according to the planned doses, and 48/60
(80%) patients received chemotherapy without decrement of the dose;
32/263 (12%) of the courses were administered with a 10%-30% dose
reduction. Complete responses (CR) were seen in 5 patients (8.3%) and
partial responses (PR) in 16 patients (26.7%) for an overall response
rate of 35%. Median duration of response was 7.5 months [95%
confidence interval (CI)-7.1-7.9], time to progression (TIP) 11.5 months
(95% CI-8.2-14.8), median overall survival (OS) 15.0 months (95%
CI-10.8-19.2). One-year survival was 61.7%. Toxicity was acceptable; it
was calculated according to the administered cycles and was mainly
neutropenia: grade 3, 9% and grade 4, 2%; anemia: grade 3, 8%; nausea
and vomiting: grade 3, 8%. The outpatient regimen of
docetaxel-carboplatin is effective with acceptable toxicity in patients
with advanced NSCLC.
Συγγραφείς:
Tsavaris, N
Kosmas, C
Skopelitis, E
Gennatas, K
Zorbala,
A
Papas, P
Gouveris, P
Antypas, G
Rokana, S and
Tzelepis, G
Λέξεις-κλειδιά:
docetaxel; carboplatin; non-small cell lung cancer
DOI:
10.1007/s00408-005-2552-5
